A Novel Non Myeloablative Regimen for Related and Unrelated Allogeneic Transplantation of High Risk Patients With Chronic Granulomatous Disease (CGD)  by Kang, E.M. et al.
Poster Session II S295conclusion, TMA is common after allo-HSCTusing SIR-containing
GVHD prophylaxis. The risk factors for TMA suggest that careful
monitoring and adjustment of TAC/SIR dosages to avoid super-
therapeutic levels is critical, particularly during ongoing GVHD.390
A NOVEL NON MYELOABLATIVE REGIMEN FOR RELATED AND UNRE-
LATED ALLOGENEIC TRANSPLANTATION OF HIGH RISK PATIENTS
WITH CHRONIC GRANULOMATOUS DISEASE (CGD)
Kang, E.M.1, Kelly, C.1, Hilligoss, D.M.1, Marquesen, M.M.1,
DeCastro, R.1, Wilder, J.2, Kwatemaa, A.N.1, Khuu, H.3,
Stroncek, D.3, Malech, H.L.1 1National Institutes of Health, Bethesda,
MD; 2National Institutes of Health, Bethesda, MD; 3National Institutes
of Health, Bethesda, MD
Allogeneic transplant can cure chronic granulomatous disease and
is increasingly being offered. However, presence of persistent unre-
sponsive severe infection deters transplant of this high-risk group,
though nonmyeloablative regimens with matched sibling donors
can succeed. In 2007 we initiated a protocol for this high-risk group
using either matched sibling or unrelated donors and show that a tol-
erance-based regimen allows for engraftment with little to no infec-
tion progression or GVHD. Using low dose Busulfan, Campath and
Rapamycin with TBI for unrelated donor recipients, we have now
transplanted 11 patients (ages 3-32); 9 with an unrelated 10/10
HLAmatched donor or a 5/6 cord blood, and 2 with a sibling donor.
We have had one primary graft failure with autologous recovery oc-
curring in the cord blood recipient who had significantly lower bu-
sulfan levels as compared to the other patients. The others all
engrafted (neutrophil count$ 500 for 3 days) by day 65 (averageday
26), showingz100% donor chimerism in the CD14/15 lineages as
measured by STR PCR. CD3 engraftment was slower with many
having less than 10%donor chimerism initially. The average number
of RBC transfusions was 2.4 units/patient with 4 patients requiring
none and 4 also not needing platelet transfusions. GVHD has been
limited to 1 patient with Grade II and 1 with Grade I of the skin.
Overall survival is 10 of 11 with 1 patient dying from non-transplant
related causes. Our longest follow up to date is 2 years in a patient
with continued full engraftment and normal immunologic function.
2 patients required a stem cell boost given without additional condi-
tioning, either for slow engraftment or unstable chimerism, and
a third patient appears to have late graft rejection with studies ongo-
ing. Most significantly, 9 of 11 patients were transplanted at the time
of an ongoing fungal or bacterial infection of lung, spine, and/or me-
ninges, often resistant to multidrug therapies. 4 patients were given
granulocyte infusions during their neutropenia. No patient had evi-
dence of infection progression, and a number showed radiologic im-
provement prior to full engraftment. Thus we have developed
a regimen with minimal GVHD, even with unrelated donors and/
or ongoing infection. Longer follow up and more patients will
help confirm our enthusiasm for this approach to treating these
high risk patients not otherwise eligible for transplant.391
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EBV remains important pathogen in patients after haematopoietic
stem cell transplantation (HSCT). Beside benign reactivation, EBV
can cause localised or generalised form of EBV associated lympho-
proliferative disease (EBV-LPD) with clinical symptoms such asfever, hepathopathy, lymphoma-like symptoms and generalised B
cell proliferation in peripheral blood.
Between I/2002 and X/2010, we tested prospectively whole blood
samples from 266 children (8,202 samples) and from 489 adults
(7,202 samples) after allogeneic HSCT. A minute number of addi-
tional tissue and body fluids samples was tested too. Retrospectively,
we tested 50 samples from 4 children who died for EBV-LPD in
2000. EBV and albumin gene were quantified using RQ-PCR and
quantity of EBV was normalised to 100,000 human genome equiva-
lents and expressed in normalised viral copies (NVCs).
In the prospective testing, EBV was detected in whole blood of
199 children (74.8%;2607 samples;median 90 normalised viral cop-
ies (NVCs) and from 301 adults (62.7%;1,749 samples;median 79
NVCs). More than 1 000 copies were detected in 62 children and
57 adults,more than 10,000 in 14 children and 13 adults. Clinical
or laboratory signs of EBV-LPD were observed in 8 children and
12 adults. Generalised EBV-LPD confirmed by detection of abnor-
mal B lymphocytes in peripheral blood was detected in 6 children
and 4 adults (mean of highest EBV 103,566 NVCs), localised form
in 2 child and 7 adults (mean of highest EBV 10,652NVCs). Despite
the rituximab treatment 3 prospectively tested adults deceased due to
treatment resistant EBV-LPD. Among retrospectively tested pa-
tients, highest quantity was between 1,165,000-11,060,500 NVCs
and the interval between the first detection of EBV and decease
was 24-91 days.
EBV can be detected in big proportion of patients after HSCT,
more frequently in paediatric population. Level of 10,000 NVCs
seems to be a good level for possible treatment and it is 100 times le-
ver than highest quantity detected patients who died of EBV-LPD.
Long lasting EBV positivity in patient with lymphomas suppose to
be EBV released from the local proliferation. Normalisation proved
to be useful approach for comparison of EBV levels in the whole
blood and in the tissues.Supported by MSMT 0021620813 and
MZ0FNM2005.392
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Objective:To investigate the distribution and the effect of killer cell
immunoglobulin-like receptor (KIR) genes, as well as to explore the
impact of different activating KIRs in HLA-identical sibling hema-
topoietic stem cell transplantation (HSCT).
Methods: The genotypes of donor/recipient KIR were determined
by polymerase chain reaction-sequence specific primer (PCR-SSP)
in 40 cases of HLA-identical sibling HSCT. And a retrospective
study was carried out to analyze the outcomes of the recipients.
Results: All the patients and the donors possessed KIR
2DL1,2DL2,2DL3,3DL2,3DL3, and 95% of individuals possessed
3DL1. The frequencies of KIR2DS4, KIR2DS1, KIR3DS1,
KIR2DS5, KIR2DS2 and KIR2DS3 were 95%, 40%, 36.25%,
31.25%, 21.25%, and 20% respectively in 40 pairs of donor-recipi-
ent. The frequencies of KIR2DS4*001/002 and 2DS4*003-007 ho-
mozygotes were 55.9% and 8.8% respectively, while the frequency
for 2DS4*001/002 and 2DS4*003-007 heterozygote was 35.3%.
Among them, 62.5% of donor/recipient KIR were completely iden-
tical, while 37.5% were not. Of the non-identical KIRs,12.5% were
the recipients KIR genotype containing the donors ones,5% were
the donors KIR containing the recipients KIR, and 20% were com-
pletely different. The donor/recipient KIR completely identical
group had higher aGVHD rate and the higher incidence of III-
IVaGVHD compared with KIR not identical group (64%
vs.26.7%, P\ 0.05 and 28% vs. 0%, P\ 0.05 respectively). The
KIR not identical group had higher 2-year disease-free survival
(DFS) compared with KIR completely identical group
[(91.6767.98)% vs. (77.7869.81)%,P 5 0.3]. The incidence of re-
lapse was 19.2% when the donor without KIR2DS2, but was 0%
for the donor with KIR2DS2. Among the A/A donors, the disease-
free survival (DFS) of one year was 70% when the donor had
2DS4*003-007,and 87.5% when the donor was KIR2DS4*001/002
